白内障手术后非增殖性向增殖性糖尿病视网膜病变进展的风险
基于TriNetX美国医疗数据(2004年6月至2024年6月)的回顾性分析,倾向性评分匹配后,接受白内障手术的2型糖尿病非增殖性糖尿病视网膜病变患者眼,术后1年进展为增殖性糖尿病视网膜病变、玻璃体积血及复合结局的风险均高于未手术眼。
要点
- 右眼分析:手术眼1年无并发症增殖性糖尿病视网膜病变风险HR 1.45(95%CI 1.09-1.92)。
- 左眼分析:手术眼1年玻璃体积血风险HR 2.12(95%CI 1.23-3.66)。
- 所有分析中牵拉性视网膜脱离或合并牵拉孔源性视网膜脱离风险无显著差异(均P>0.05)。
核心结论
- 现代白内障手术与2型糖尿病非增殖性糖尿病视网膜病变患者术后1年内进展为增殖性糖尿病视网膜病变相关。
研究设计与样本
- 回顾性分析2004年6月至2024年6月TriNetX美国协作研究网络的汇总医疗数据。
- 研究对象为18岁及以上患有2型糖尿病和非增殖性糖尿病视网膜病变的患者,分为接受常规白内障手术组和未接受白内障手术组。
- 采用倾向性评分匹配平衡基线人口学和临床特征,按眼进行分析。
- 计算风险比(HR)及95%置信区间(CI),并进行敏感性分析评估白内障手术前2型糖尿病病程至少5年的患者。
主要发现
- 右眼分析匹配后手术组3589例、对照组3589例,手术眼1年无并发症增殖性糖尿病视网膜病变风险HR 1.45(95%CI 1.09-1.92)。
- 右眼分析手术眼1年玻璃体积血风险HR 1.92(95%CI 1.13-3.25),复合结局风险HR 1.49(95%CI 1.13-1.96)。
- 左眼分析匹配后手术组3616例、对照组3616例,手术眼1年无并发症增殖性糖尿病视网膜病变风险HR 1.58(95%CI 1.17-2.13)。
- 左眼分析手术眼1年玻璃体积血风险HR 2.12(95%CI 1.23-3.66),复合结局风险HR 1.60(95%CI 1.21-2.13)。
- 敏感性分析匹配后手术组2488例、对照组2488例,手术眼1年无并发症增殖性糖尿病视网膜病变风险HR 1.52(95%CI 1.06-2.19)。
关键数值与推荐
- 右眼分析主要结局:无并发症增殖性糖尿病视网膜病变HR 1.45(95%CI 1.09-1.92),玻璃体积血HR 1.92(95%CI 1.13-3.25),复合结局HR 1.49(95%CI 1.13-1.96)。
- 左眼分析主要结局:无并发症增殖性糖尿病视网膜病变HR 1.58(95%CI 1.17-2.13),玻璃体积血HR 2.12(95%CI 1.23-3.66),复合结局HR 1.60(95%CI 1.21-2.13)。
- 敏感性分析主要结局:无并发症增殖性糖尿病视网膜病变HR 1.52(95%CI 1.06-2.19),玻璃体积血HR 2.50(95%CI 1.20-5.20),复合结局HR 1.75(95%CI 1.22-2.51)。
- 所有分析中牵拉性视网膜脱离或合并牵拉孔源性视网膜脱离风险无显著差异(均P>0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the influence of modern cataract surgery on the progression from nonproliferative diabetic retinopathy (NPDR) to proliferative diabetic retinopathy (PDR) in patients with type 2 diabetes (T2D). DESIGN: A retrospective analysis of aggregated healthcare data from June 2004 to June 2024 within the TriNetX U.S. collaborative research network. SUBJECTS: Patients 18 years or older with T2D and NPDR who either underwent routine cataract surgery or did not receive cataract surgery. METHODS: We used the TriNetX integrated analytics platform to analyze data from U.S. healthcare organizations and conducted propensity score matching (PSM) to balance baseline demographic and clinical characteristics. We performed analysis by eye. We calculated hazard ratios (HRs) with 95% confidence intervals (CIs) and performed a sensitivity analysis evaluating patients with at least 5 years of T2D before cataract surgery. MAIN OUTCOME MEASURES: Risk of first-time PDR diagnosis, vitreous hemorrhage (VH), tractional retinal detachment (TRD) or combined tractional and rhegmatogenous retinal detachment (CTRD), and a composite outcome at 1 year in patients who underwent cataract surgery relative to those who did not. RESULTS: Post-PSM, there were 7178 patients in the study (n = 3589) and control (n = 3589) cohorts for right eye analysis; increased 1-year risks of PDR without complications (HR, 1.45; 95% CI, 1.09-1.92), VH (HR, 1.92; 95% CI, 1.13-3.25), and the composite outcome (HR, 1.49; 95% CI, 1.13-1.96) were observed in operated eyes. Left eye analysis included 7232 patients in the study (n = 3616) and control (n = 3616) cohorts post-PSM; increased 1-year risks of PDR without complications (HR, 1.58; 95% CI, 1.17-2.13), VH (HR, 2.12; 95% CI, 1.23-3.66), and the composite outcome (HR, 1.60; 95% CI, 1.21-2.13) were observed in operated eyes. Sensitivity analysis of those with at least 5 years of T2D included 4976 patients in the study (n = 2488) and control (n = 2488) cohorts post-PSM; increased 1-year risks of PDR without complications (HR, 1.52; 95% CI, 1.06-2.19), VH (HR, 2.50; 95% CI, 1.20-5.20), and the composite outcome (HR, 1.75; 95% CI, 1.22-2.51) were observed in operated eyes. There was no significant difference in the risk for TRD or CTRD in all analyses (all P > 0.05). CONCLUSIONS: Modern cataract surgery was associated with progression from T2D NPDR to PDR within 1 year postoperatively. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
引用
- Loya A, Hussain ZS, Muayad J, et al. Risk of Progression of Nonproliferative to Proliferative Diabetic Retinopathy after Cataract Surgery. Ophthalmology. 2025. PMID: 39956206. doi:10.1016/j.ophtha.2025.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。